Effects Of Once-Weekly Subcutaneous Semaglutide On Kidney Function And Safety In Patients With Type

In view of the high risk of developing chronic kidney disease in patients with type 2 diabetes, researchers investigated the impact of semaglutide on kidney function and safety in a large, broad type 2 diabetes (T2D) population. A post-hoc analysis of 8,416 T2D patients participating in the SUSTAIN 1–5 and SUSTAIN 7 randomised controlled trials, and the SUSTAIN 6 cardiovascular outcomes trial was performed to investigate the impact of once-weekly subcutaneous semaglutide 0·5 mg and 1·0 mg vs comparators (active treatments or placebo) on estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR), and kidney adverse events. Across the SUSTAIN 1–7 trials, semaglutide was correlated with initial declines in eGFR that plateaued and marked reductions in UACR. This post-hoc analysis indicates no rise in the risk of kidney adverse events with semaglutide vs the active comparators used across SUSTAIN 1–7.

​

Source